NVP-BEZ235 is an oral bioavailable, reversing, ATP-competitive dual PI3K and mTORC1/2 inhibitor, largely used in preclinical studies on several cancers comprising GBM, breast, colorectal, and lung cancers [146,147,148,149]. This evidence concerns the gene PIK3CD and cancer.